The NEPTUNE research study is seeking volunteers to assess the safety and effectiveness of an investigational treatment for adults with non-infectious uveitis.
This is a randomized, double-masked, dose-ranging phase 2 study to evaluate the efficacy and safety of oral brepocitinib in adults with active intermediate-, posterior or panuveitis. Eligible participants will be randomly assigned 2:1 to one of the 2 investigational treatment arms (45 mg or 15 mg) administered orally once per day, for up to 52 weeks. There is no placebo treatment in this study. Approximately 24 participants will be enrolled in the study.
Participants enrolled in the NEPTUNE study will attend 13 office visits over the course of approximately 52 weeks. Your insurance will not be billed for study activities.
PARTICIPANTS MAY QUALIFY IF THEY:
- Have been diagnosed with Non-Infectious Uveitis
- Between the ages of 18-74
IF QUALIFIED, PARTICIPANTS MAY RECIEVE:
- No cost for study medication
- Care from a doctor specializing in uveitis treatment
- Compensation for time and travel
The Study is currently recruiting participants across various investigating sites in the United States. More information can be found at neptunestudy.com and https://clinicaltrials.gov/ct2/show/NCT05523765.